Literature DB >> 32002671

The Burden of Cost in Inflammatory Bowel Disease: A Medical Economic Perspective and the Future of Value-Based Care.

Jonathan A Beard1, Diana L Franco1, Benjamin H Click2.   

Abstract

PURPOSE OF REVIEW: To examine the quantifiable economic impact of inflammatory bowel disease (IBD), key cost drivers and determinants, and the impact of value-based care in IBD. Finally, we prognosticate on future directions and opportunities on healthcare economics in IBD. RECENT
FINDINGS: New value-based initiatives, technologically driven interventions, and quality improvement programs have demonstrated reductions in healthcare utilization and enhanced patient outcomes, and several have realized cost of care reductions. IBD is a costly, chronic illness with unbalanced spending by a small proportion of individuals. Pharmaceutical costs are overtaking inpatient expenses as the primary cost driver. Value-based care initiatives including the IBD medical home, remote monitoring platforms such as myIBDcoach and Project Sonar, and learning healthcare networks exemplified by ImproveCareNow have all demonstrated successes in improving care quality, patient outcomes, and reduced healthcare spending in some populations. The future of value-based care in IBD is bright, with ample opportunities for model refinement, collaboration, and growth.

Entities:  

Keywords:  Biologics; Cost; Donabedian; Inflammatory bowel disease; Patient-centered medical home; Quality; Specialty medical home; Value-based care

Mesh:

Year:  2020        PMID: 32002671     DOI: 10.1007/s11894-020-0744-z

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  49 in total

1.  Acceptance of telemanagement is high in patients with inflammatory bowel disease.

Authors:  Raymond K Cross; Mohit Arora; Joseph Finkelstein
Journal:  J Clin Gastroenterol       Date:  2006-03       Impact factor: 3.062

2.  Evaluating the quality of medical care. 1966.

Authors:  Avedis Donabedian
Journal:  Milbank Q       Date:  2005       Impact factor: 4.911

3.  Predictors of severe Crohn's disease.

Authors:  Catherine Loly; Jacques Belaiche; Edouard Louis
Journal:  Scand J Gastroenterol       Date:  2008-08       Impact factor: 2.423

Review 4.  Inflammatory bowel disease: a Canadian burden of illness review.

Authors:  Angela Rocchi; Eric I Benchimol; Charles N Bernstein; Alain Bitton; Brian Feagan; Remo Panaccione; Kevin W Glasgow; Aida Fernandes; Subrata Ghosh
Journal:  Can J Gastroenterol       Date:  2012-11       Impact factor: 3.522

5.  Incidence Rates and Predictors of Colectomy for Ulcerative Colitis in the Era of Biologics: Results from a Provincial Database.

Authors:  Maria Abou Khalil; Marylise Boutros; Hacene Nedjar; Nancy Morin; Gabriela Ghitulescu; Carol-Ann Vasilevsky; Philip Gordon; Elham Rahme
Journal:  J Gastrointest Surg       Date:  2017-08-14       Impact factor: 3.452

Review 6.  Defining quality indicators for best-practice management of inflammatory bowel disease in Canada.

Authors:  Geoffrey C Nguyen; Shane M Devlin; Waqqas Afif; Brian Bressler; Steven E Gruchy; Gilaad G Kaplan; Liliana Oliveira; Sophie Plamondon; Cynthia H Seow; Chadwick Williams; Karen Wong; Brian M Yan; Jennifer Jones
Journal:  Can J Gastroenterol Hepatol       Date:  2014-05

Review 7.  ImproveCareNow: The development of a pediatric inflammatory bowel disease improvement network.

Authors:  Wallace Crandall; Michael D Kappelman; Richard B Colletti; Ian Leibowitz; John E Grunow; Sabina Ali; Howard I Baron; James H Berman; Brendan Boyle; Stanley Cohen; Fernando del Rosario; Lee A Denson; Lynn Duffy; Mark J Integlia; Sandra C Kim; David Milov; Ashish S Patel; Bess T Schoen; Dorota Walkiewicz; Peter Margolis
Journal:  Inflamm Bowel Dis       Date:  2011-01       Impact factor: 5.325

8.  An evaluation of health care expenditures in Crohn's disease using the United States Medical Expenditure Panel Survey from 2003 to 2013.

Authors:  Mark Bounthavong; Meng Li; Jonathan H Watanabe
Journal:  Res Social Adm Pharm       Date:  2016-05-20

9.  Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease-an International, Cross-disciplinary Consensus.

Authors:  Andrew H Kim; Charlotte Roberts; Brian G Feagan; Rupa Banerjee; Willem Bemelman; Keith Bodger; Marc Derieppe; Axel Dignass; Richard Driscoll; Ray Fitzpatrick; Janette Gaarentstroom-Lunt; Peter D Higgins; Paulo Gustavo Kotze; Jillian Meissner; Marian O'Connor; Zhi-Hua Ran; Corey A Siegel; Helen Terry; Welmoed K van Deen; C Janneke van der Woude; Alandra Weaver; Suk-Kyun Yang; Bruce E Sands; Séverine Vermeire; Simon Pl Travis
Journal:  J Crohns Colitis       Date:  2018-03-28       Impact factor: 9.071

Review 10.  Indirect costs of inflammatory bowel diseases: Crohn's disease and ulcerative colitis. A systematic review.

Authors:  Paweł Kawalec
Journal:  Arch Med Sci       Date:  2016-04-12       Impact factor: 3.318

View more
  5 in total

1.  Mobile Apps for the Management of Gastrointestinal Diseases: Systematic Search and Evaluation Within App Stores.

Authors:  Eva-Maria Messner; Niklas Sturm; Yannik Terhorst; Lasse B Sander; Dana Schultchen; Alexandra Portenhauser; Simone Schmidbaur; Michael Stach; Jochen Klaus; Harald Baumeister; Benjamin M Walter
Journal:  J Med Internet Res       Date:  2022-10-05       Impact factor: 7.076

2.  Carnosol Maintains Intestinal Barrier Function and Mucosal Immune Homeostasis in DSS-Induced Colitis.

Authors:  Xiang Xu; Gao Zhang; Kun Peng; Yanping Gao; Jinxia Wang; Caiping Gao; Chong He; Fang Lu
Journal:  Front Nutr       Date:  2022-05-24

3.  Optimizing biologic therapy in inflammatory bowel disease: a Delphi consensus in the United Arab Emirates.

Authors:  Vito Annese; Rahul Nathwani; Maryam Alkhatry; Ahmad Al-Rifai; Sameer Al Awadhi; Filippos Georgopoulos; Ahmad N Jazzar; Ahmed M Khassouan; Zaher Koutoubi; Mazen S Taha; Jimmy K Limdi
Journal:  Therap Adv Gastroenterol       Date:  2021-12-22       Impact factor: 4.409

4.  A Novel Neutrophil-Based Biomarker to Monitor Disease Activity and Predict Response to Infliximab Therapy in Patients With Ulcerative Colitis.

Authors:  Zhou Zhou; Yinghui Zhang; Yan Pan; Xue Yang; Liangping Li; Caiping Gao; Chong He
Journal:  Front Med (Lausanne)       Date:  2022-04-27

Review 5.  A Narrative Review of Factors Historically Influencing Telehealth Use across Six Medical Specialties in the United States.

Authors:  Pavani Rangachari; Swapandeep S Mushiana; Krista Herbert
Journal:  Int J Environ Res Public Health       Date:  2021-05-08       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.